2026-03-30 12:45:51
Veradermics Reports Q4 and Full Year 2025 Financial Results with Positive Clinical Updates
Expected Stock impact: Slightly Positive
On March 30, 2026, Veradermics, Incorporated (NYSE: MANE) announced its financial results for the fourth quarter and the full year ended December 31, 2025. The company reported a net loss of $21.8 million for the fourth quarter, compared to a net loss of $5.7 million for the same period in 2024. For the full year, the net loss was $70.0 million, up from $26.5 million in 2024. Despite the losses, Veradermics highlighted significant progress in its clinical trials, particularly with its lead product candidate, VDPHL01, an oral treatment for pattern hair loss. The company completed enrollment in two pivotal trials for VDPHL01, with topline data expected in the first half of 2026. Additionally, Veradermics successfully closed an upsized IPO of approximately $294.8 million in February 2026, which is expected to fund operations through 2029. The company is focused on advancing its clinical programs and preparing for potential regulatory submissions. CEO Reid Waldman emphasized the company's commitment to providing new treatment options for patients suffering from hair loss, stating, 'This year, we expect two Phase 3 readouts in men and to continue to make progress toward a planned NDA submission.' The financial results and clinical updates indicate a strategic focus on operational execution and a positive outlook for the company's future.
